Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec;28(12):956-958.
doi: 10.1016/j.tim.2020.10.004. Epub 2020 Oct 14.

The Mystery of MIS-C Post-SARS-CoV-2 Infection

Nina N Brodsky  1 , Anjali Ramaswamy  2 , Carrie L Lucas  3
Affiliations
Comment

The Mystery of MIS-C Post-SARS-CoV-2 Infection

Nina N Brodsky et al. Trends Microbiol. 2020 Dec.

Abstract

Following emergence of the coronavirus disease 2019 (COVID-19) pandemic, a surge in the life-threatening illness now termed 'multisystem inflammatory syndrome in children' (MIS-C) has raised questions about the unique effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in children and adolescents. Two important new studies by Consiglio et al. and Gruber et al. have begun to shine light on the immune drivers of this enigmatic disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MIS-C Occurs 4–6 Weeks after SARS-CoV-2 Infection in Children and Adolescents and Is Characterized by a Cytokine Storm Involving Innate and Adaptive Immune Cells. The self-limiting acute inflammatory episode in MIS-C is characterized by tissue damage affecting several organ systems and the coronary arteries and is associated with potential extravasation of innate immune cells, activation of T cells, and autoantibodies. The figure was generated with Biorender.com. Abbreviations: DC, dendritic cell; HLA-DR, human leukocyte antigen-DR; IL, interleukin, MIS-C, multisystem inflammatory syndrome in children; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
See this image and copyright information in PMC

Comment on

  • The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19.
    Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, Tan Z, Zicari S, Ruggiero A, Pascucci GR, Santilli V, Campbell T, Bryceson Y, Eriksson D, Wang J, Marchesi A, Lakshmikanth T, Campana A, Villani A, Rossi P; CACTUS Study Team; Landegren N, Palma P, Brodin P. Consiglio CR, et al. Cell. 2020 Nov 12;183(4):968-981.e7. doi: 10.1016/j.cell.2020.09.016. Epub 2020 Sep 6. Cell. 2020. PMID: 32966765 Free PMC article.

References

    1. Dufort E.M. Multisystem inflammatory syndrome in children in New York State. N. Engl. J. Med. 2020;383:347–358. - PMC - PubMed
    1. Feldstein L.R. Multisystem inflammatory syndrome in U.S. children and adolescents. N. Engl. J. Med. 2020;383:334–346. - PMC - PubMed
    1. Whittaker E. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. JAMA. 2020;324:259–269. - PMC - PubMed
    1. Rowley A.H. Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. Nat. Rev. Immunol. 2020;20:453–454. - PMC - PubMed
    1. Son M.B. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009;124:1–8. - PubMed

Supplementary concepts